Anti-inflammatory Therapeutics Market is estimated to increase at a growth rate of 6.3% CAGR over the forecast period from 2024 to 2030.
The global Anti-inflammatory Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Drug Class (Nonsteroidal Anti-inflammatory Diseases (NSAIDs), Corticosteroids, Biologics), By Indication (Arthritis, Respiratory Disease, Multiple Sclerosis, Psoriasis, Anti-inflammatory Bowel Disease (IBD), Others).
An Introduction to Anti-inflammatory Therapeutics Market in 2024
The Anti-inflammatory Therapeutics Market in 2024 encompasses pharmaceuticals and biologics targeting inflammatory pathways, immune responses, and cytokine signaling to treat inflammatory disorders and autoimmune diseases. These therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, biologics like TNF inhibitors and interleukin blockers, and novel anti-inflammatory agents. With a focus on reducing inflammation, pain relief, and disease management in conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis, anti-inflammatory therapeutics play a vital role in improving patient outcomes and quality of life.
Anti-inflammatory Therapeutics Market Competitive Landscape
The global Anti-inflammatory Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Anti-inflammatory Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Anti-inflammatory Therapeutics Industry include- AbbVie Inc, Alvogen Iceland ehf, Amgen Inc, Amneal Pharmaceuticals Inc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd, Cipla Ltd, Eli Lilly and Co., F. Hoffmann-La Roche Ltd, Ferring BV, Johnson and Johnson, Lupin Ltd, Mylan N.V.
Anti-inflammatory Therapeutics Market Trend: Increasing Focus on Targeted Therapies and Precision Medicine
In the Anti-inflammatory Therapeutics market, a significant trend is the increasing focus on targeted therapies and precision medicine. With a growing understanding of the molecular pathways involved in inflammatory diseases, there's a shift towards developing therapies that selectively target specific inflammatory mediators or signaling pathways, while minimizing off-target effects and systemic immunosuppression. This trend drives market growth by offering more tailored and effective treatment options for patients with inflammatory conditions, leading to the development of novel biologic agents, small molecule inhibitors, and personalized treatment approaches.
Anti-inflammatory Therapeutics Market Driver: Rising Prevalence of Chronic Inflammatory Disorders
A key driver for the Anti-inflammatory Therapeutics market is the rising prevalence of chronic inflammatory disorders worldwide. Conditions such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and asthma impose a significant burden on healthcare systems and patient quality of life, driving the demand for effective anti-inflammatory treatments that can manage symptoms, prevent disease progression, and improve long-term outcomes. This demographic and epidemiological shift fuels market demand for a wide range of anti-inflammatory drugs and biologics across diverse therapeutic areas.
Anti-inflammatory Therapeutics Market Opportunity: Development of Novel Therapeutic Modalities
An opportunity exists in the development of novel therapeutic modalities for anti-inflammatory intervention. By exploring innovative drug targets, mechanisms of action, and delivery systems, there's potential to expand the therapeutic landscape beyond conventional immunosuppressive agents and biologic therapies. This includes the exploration of gene editing technologies, RNA-based therapeutics, microbiome-targeted interventions, and immune-modulating nanoparticles, among others, offering new avenues for market innovation, differentiation, and therapeutic advancement in the Anti-inflammatory Therapeutics segment.
Market Share Analysis: Biologics for Psoriasis Indication is the fastest growing segment in the Anti-inflammatory Therapeutics industry
Within the segmentation of Anti-inflammatory Therapeutics, the segment of Biologics for Psoriasis Indication emerges as the fastest-growing. This growth is driven by several significant factors. Psoriasis is a chronic inflammatory skin condition characterized by red, itchy patches of skin covered with silvery scales. Biologic therapies have revolutionized the treatment landscape for psoriasis by offering targeted and effective options for patients with moderate to severe disease who are unresponsive or intolerant to traditional therapies. Biologics work by inhibiting specific molecules involved in the inflammatory pathways implicated in psoriasis, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-17 (IL-17), and interleukin-23 (IL-23). By targeting these key mediators, biologics effectively suppress inflammation and reduce the severity of psoriatic lesions, leading to significant improvements in symptoms, quality of life, and long-term disease management. Moreover, biologic therapies offer advantages such as improved efficacy, rapid onset of action, and reduced systemic side effects compared to conventional treatments like corticosteroids and NSAIDs. The growing prevalence of psoriasis, coupled with the increasing demand for safe and effective long-term treatment options, drives the adoption of biologics in the management of this debilitating condition. Additionally, ongoing research and development efforts focused on expanding the biologic armamentarium for psoriasis further contribute to the rapid growth of this segment. As a result, the segment of Biologics for Psoriasis Indication experiences significant growth, driven by the increasing recognition of their therapeutic benefits and expanding utilization in the management of psoriasis.
Anti-inflammatory Therapeutics Market Segmentation
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Anti-inflammatory Therapeutics Companies
AbbVie Inc
Alvogen Iceland ehf
Amgen Inc
Amneal Pharmaceuticals Inc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Cadila Pharmaceuticals Ltd
Cipla Ltd
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd
Ferring BV
Johnson and Johnson
Lupin Ltd
Mylan N.V
* List not Exhaustive
Reasons to Buy the Anti-inflammatory Therapeutics Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Anti-inflammatory Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Anti-inflammatory Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Anti-inflammatory Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Anti-inflammatory Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Anti-inflammatory Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Anti-inflammatory Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Anti-inflammatory Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Anti-inflammatory Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Anti-inflammatory Therapeutics Industry
4.2 Key Market Trends in Anti-inflammatory Therapeutics Industry
4.3 Potential Opportunities in Anti-inflammatory Therapeutics Industry
4.4 Key Challenges in Anti-inflammatory Therapeutics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Anti-inflammatory Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Anti-inflammatory Therapeutics Market Outlook by Segments
7.1 Anti-inflammatory Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
8 North America Anti-inflammatory Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Anti-inflammatory Therapeutics Markets in 2024
8.2 North America Anti-inflammatory Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Anti-inflammatory Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
9 Europe Anti-inflammatory Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Anti-inflammatory Therapeutics Markets in 2024
9.2 Europe Anti-inflammatory Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Anti-inflammatory Therapeutics Market Size Outlook by Segments, 2021-2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
10 Asia Pacific Anti-inflammatory Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Anti-inflammatory Therapeutics Markets in 2024
10.2 Asia Pacific Anti-inflammatory Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Anti-inflammatory Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
11 South America Anti-inflammatory Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Anti-inflammatory Therapeutics Markets in 2024
11.2 South America Anti-inflammatory Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Anti-inflammatory Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
12 Middle East and Africa Anti-inflammatory Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Anti-inflammatory Therapeutics Markets in 2024
12.2 Middle East and Africa Anti-inflammatory Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Anti-inflammatory Therapeutics Market size Outlook by Segments, 2021-2030
By Drug Class
Nonsteroidal Anti-inflammatory Diseases (NSAIDs)
Corticosteroids
Biologics
By Indication
Arthritis
Respiratory Disease
Multiple Sclerosis
Psoriasis
Anti-inflammatory Bowel Disease (IBD)
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Alvogen Iceland ehf
Amgen Inc
Amneal Pharmaceuticals Inc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Cadila Pharmaceuticals Ltd
Cipla Ltd
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd
Ferring BV
Johnson and Johnson
Lupin Ltd
Mylan N.V
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
